# 8) Vaccine Acceleration By Modular Progression - Enhanced Biological Defense (VAMP-ENBD)

**R-2A activity** of project PT4 — Protect (ACD&P)  
**Program element:** 0603884BP — Chemical and Biological Defense Program - Dem/Val  
**Component:** Defense-Wide · **Budget Activity:** 4  
**Vintage:** President's Budget PB2027  
**Canonical URL:** https://hitchintel.com/programs/0603884BP/PT4/a7  
**Parent:** https://hitchintel.com/programs/0603884BP/PT4

## Summary

This activity requests $31.1M in FY2027, 24% of project PT4, down 42% on FY2026. The R-2A exhibit describes it across FY2025–FY2027, including what the FY2027 money is planned to buy.

## What the FY2027 request buys

**FY2027 planned work.** Continue development and manufacturing of multiple vaccine candidates against biothreats. Continue test and evaluation efforts in safety and efficacy clinical trials.

**FY2026 to FY2027 change.** FY 2026 to FY 2027 decrease is due to fewer additional manufacturing and clinical trial efforts compared to FY 2026.

## Before the request year

**FY2026 plans — current year.** Continue development and manufacturing of multiple vaccine candidates against biothreats. Continue test and evaluation efforts in safety and efficacy clinical trials. Add manufacturing and clinical trials for plague vaccine.

**FY2025 accomplishments.** Continued development and manufacturing of vaccine candidates against multiple biothreats. Continued test and evaluation efforts in safety and efficacy clinical trials. Initiated several clinical trials.

## Funding

| Fiscal Year | Estimate Type | Amount ($M) |
|---|---|---|
| FY2025 | Actual | 50.2 |
| FY2026 | Enacted | 53.3 |
| FY2027 | Request | 31.1 |

> Prior, current and budget year only — an R-2A activity carries no five-year plan. It sums exactly into its project in the request year and not necessarily in any other.

## Other activities in project PT4

- [3) Generative Unconstrained Intelligent Drug Engineering - Enhanced Biological Defense (GUIDE-ENBD)](https://hitchintel.com/programs/0603884BP/PT4/a2) — FY2027 45.5
- [1) Accelerated Antibodies - Enhanced Biological Defense (AA-ENBD)](https://hitchintel.com/programs/0603884BP/PT4/a0) — FY2027 32.1
- 5) Medical Countermeasures Platform Technologies (MCMPT) - Host Directed Countermeasure — FY2027 9.0
- 7) Prophylactic Technology Systems (ProTecS) — FY2027 7.3
- 4) Medical Countermeasures Platform Technologies (MCMPT) - Prevention Platform — FY2027 3.8
- 6) Plague Monoclonal Antibodies (PLG MAB) — FY2027 0.5
- 2) Biological Containment Isolation System - Enhanced Biological Defense (BCIS-ENBD) — FY2027 —
- 9) Portable Patient Transport System - Enhanced Biological Defense (PPTS-ENBD) — FY2027 —
- 10) Shipboard Isolation System (SIS) — FY2027 —

## Source & machine access

- **Source:** FY2027 Office of the Secretary of Defense RDT&E Budget Justification, Exhibit R-2A, PE 0603884BP project PT4 (PB PB2027). Narrative is the government's own text.
- **No marks, no contractors at this grain** — congressional marks land on the program element and R-3 performers on the project.
- **MCP:** `mcp.hitchintel.com` — `budget_get_activity`.

*HitchAI is an independent intelligence service, not affiliated with the U.S. Department of Defense. Budget figures are requests/estimates, not obligations.*